Shares of Capricor Therapeutics (NASDAQ:CAPR) experienced a dramatic decline of 67.4% on Monday, falling to $6.42 per share and reducing the company's market capitalization to approximately $370 million. The steep drop came after U.S. Food and Drug Administration (FDA) staff raised significant concerns regarding the efficacy data for deramiocel, the company's investigational treatment for Duchenne muscular dystrophy (DMD).
FDA Review Raises Red Flags
According to FDA briefing documents, the planned analyses of the HOPE-3 clinical trial failed to achieve statistical significance for both arm function and heart function endpoints. The analysis of arm function showed a difference of 0.66 points between the treatment and placebo groups, with a p-value of 0.24, falling short of the threshold for statistical significance. Capricor's subsequent post-hoc analysis using percentages reported a 4.55% difference with a p-value of 0.029, but FDA reviewers criticized this approach as lacking scientific rationale and diminishing precision.
Similarly, the analysis of heart function, specifically left ventricular ejection fraction, showed no significant benefit, with a negative difference of 0.041 percentage points and a p-value of 0.97. A ranked analysis yielded a p-value of 0.041, but reviewers noted that nearly 22% of randomized patients were excluded from this analysis, introducing potential bias.
Safety Concerns Emerge
Safety data also raised concerns. Hypersensitivity reactions were observed in 41.5% of patients receiving deramiocel, compared to 15.4% in the placebo group. The FDA also questioned whether the study population adequately represented patients with DMD-related cardiomyopathy, as the average baseline heart function was 57%, with only 4.7% of participants falling below 45%.
Market Impact and Context
The decline erased approximately $766 million in equity value, leaving the market capitalization minus reported cash at just $92 million, a steep drop from $858 million on Friday. Notably, the sell-off was not part of a broader biotech downturn, as the SPDR S&P Biotech ETF (NYSEARCA:XBI) rose 1.0% on the same day. Peer companies in the DMD space, including Sarepta Therapeutics (NASDAQ:SRPT), Edgewise Therapeutics (NASDAQ:EWTX), and Dyne Therapeutics (NASDAQ:DYN), all saw gains.
Advisory Committee and Regulatory Outlook
An FDA advisory committee is scheduled to convene on July 29 to review the data and vote on the drug's benefit-risk profile. While the committee's recommendation is not binding, it carries significant weight in the FDA's final decision, which is expected by August 22. This application was submitted after a Complete Response Letter was issued in July 2025. Currently, there are no FDA-approved treatments specifically targeting cardiomyopathy associated with Duchenne muscular dystrophy.
Analyst and Management Reactions
Chief Executive Linda Marbán expressed being "completely shocked" by the FDA's findings. Capricor noted that it had provided a revised statistical plan in September 2025, finalizing it in November. Analyst Kristen Kluska of Cantor Fitzgerald stated that the documents presented "many more concerns" than anticipated, putting Capricor in a difficult position ahead of the advisory committee meeting.
Financial Position and Future Risks
Capricor reported operating cash usage of $29.3 million in the first quarter, with management indicating that existing funds are expected to be sufficient through the fourth quarter of 2027. The primary risk for investors is a potential further delay, additional study requirement, or outright rejection, which would prolong costs before any potential revenue. Conversely, a positive outcome could boost the stock, though the FDA is not obligated to follow the panel's recommendation.
